{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:45:09Z","timestamp":1792028709218,"version":"4.4.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.eururo.2022.05.025","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T17:21:54Z","timestamp":1654622514000},"page":"385-390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Extensive 177Lu-PSMA Radioligand Therapy Can Lead to Radiation Nephropathy with a Renal Thrombotic Microangiopathy\u2013like Picture"],"prefix":"10.1016","volume":"83","author":[{"given":"Hannah","family":"Sch\u00e4fer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"B\u00fcttner-Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Knorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Steinhelfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten A.","family":"B\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen E.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Heemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schmaderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2022.05.025_b0005","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","article-title":"Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer","volume":"75","author":"Heck","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.05.025_b0010","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2022.05.025_b0015","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/ckj\/sfz101","article-title":"Renal outcomes of radioligand therapy: experience of 177lutetium\u2013prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer","volume":"13","author":"Gallyamov","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.eururo.2022.05.025_b0020","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","article-title":"EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)","volume":"46","author":"Kratochwil","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2022.05.025_b0025","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00259-017-3681-9","article-title":"The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer","volume":"44","author":"Yordanova","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2022.05.025_b0030","doi-asserted-by":"crossref","first-page":"644","DOI":"10.2967\/jnumed.118.215715","article-title":"Early experience of rechallenge 177Lu-PSMA radioligand therapy after an initial good response in patients with advanced prostate cancer","volume":"60","author":"Gafita","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2022.05.025_b0035","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.ijrobp.2007.12.009","article-title":"Impact of drug therapy, radiation dose, and dose rate on renal toxicity following bone marrow transplantation","volume":"71","author":"Cheng","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2022.05.025_b0040","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1002\/1097-0142(19910601)67:11<2795::AID-CNCR2820671114>3.0.CO;2-D","article-title":"Late renal dysfunction in adult survivors of bone marrow transplantation","volume":"67","author":"Lawton","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2022.05.025_b0045","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0272-6386(01)80135-9","article-title":"A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy","volume":"37","author":"Moll","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.eururo.2022.05.025_b0050","first-page":"659","article-title":"Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes","volume":"57","author":"Duncan","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2022.05.025_b0055","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.eururo.2022.05.025_b0060","first-page":"619","article-title":"Is the renal dosimetry for [90Y-DOTA0, Tyr3]octreotide accurate enough to predict thresholds for individual patients?","volume":"18","author":"Konijnenberg","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.eururo.2022.05.025_b0065","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1007\/s00259-017-3678-4","article-title":"Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry","volume":"44","author":"Sundl\u00f6v","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2022.05.025_b0070","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s00259-008-0778-1","article-title":"Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors","volume":"35","author":"Bodei","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2022.05.025_b0075","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2967\/jnumed.116.178483","article-title":"Radiation dosimetry for 177Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions","volume":"58","author":"Okamoto","year":"2017","journal-title":"J Nucl Med"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822024010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822024010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:13:36Z","timestamp":1759583616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283822024010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0302283822024010"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2022.05.025","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extensive 177Lu-PSMA Radioligand Therapy Can Lead to Radiation Nephropathy with a Renal Thrombotic Microangiopathy\u2013like Picture","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2022.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}